They Tried to Make This Molecule Illegal in 2022.
Here's What They Don't Want You to Know.
On November 4, 2022, the FDA quietly tried to pull NMN off the market — the same molecule Harvard researchers have spent forty years calling the most promising compound in human longevity. They didn't issue a press release. They didn't warn consumers. They just changed the classification. This is what actually happened, who profits if they try again, and why I'm protecting my protocol while I still can.
Editorial portrait
Man 55-58
Reading documents under lamp light
Focused, controlled anger
Investigative aesthetic
November 4, 2022.
The Day They Almost Took It Away.
In November 2022, the FDA quietly attempted to pull one of the most-researched supplements in modern science off the United States market. There was no press release. No public warning. No 60 Minutes segment. Just a regulatory line item, buried in agency communications, that should have ended NMN — nicotinamide mononucleotide — as a legal supplement overnight.
It didn't end. Because of who fought back, and how loudly. But what most consumers still don't know is why the FDA tried it in the first place — and who stood to profit if it had succeeded.
This is what the public record shows.
In 2017, a biotech firm with research ties to Harvard began clinical trials on NMN as a pharmaceutical drug. By 2022, that filing — an Investigational New Drug application, or IND — was being used to argue that NMN could no longer legally be sold as a dietary supplement. The FDA agreed.
Under a regulation called the Drug Exclusion Provision, the same molecule that millions of Americans were already taking safely could now be claimed by a single company. Repackaged. Re-priced. Sold by prescription only. The supplement industry estimated the prescription cost at roughly $600 a month.
FDA documents under desk lamp
Highlighter marks, redacted lines
Investigative journalism aesthetic
Hands holding patent document
Highlighter, magnifying glass
Here's how the game is played.
A natural compound exists. People take it. Researchers prove it works. Sales grow. Lives improve. Most companies, most ingredients, this story stops there.
But occasionally, a pharmaceutical company looks at a supplement market and sees a different opportunity. They take the same molecule, file it as an "Investigational New Drug" — an IND — with the FDA. They run a clinical trial. They build a patent moat.
And then, under a rule called the Drug Exclusion Provision, the molecule becomes theirs. It can no longer be sold as a supplement. Anyone who wants to take it has to wait for the prescription version. At prescription pricing.
Two bottles side by side:
Prescription vs supplement
This isn't a theory. It's the playbook.
It's how a $4 vitamin B3 derivative became a $600/month prescription. How a melatonin variant became a controlled substance in much of Europe. How dozens of natural compounds have quietly been pulled from supplement shelves over the last twenty years.
And in 2022, NMN — the most well-studied longevity molecule on the planet — almost joined the list.
A single biotech firm had filed it. The FDA had agreed. The countdown had started. What stopped it wasn't a sense of justice. It was the supplement industry trade group filing a counter-petition, hundreds of thousands of consumers writing in, and a 2025 reversal that the FDA quietly issued without explanation.
They didn't lose because they were wrong.
They lost because they got caught.
The 2025 reversal isn't permanent. They can file again, anytime. I'm not waiting to find out.
Protect My ProtocolFour Dates. One Pattern.
If you want to know who actually decides what you can put in your body, follow the paper trail. Here's the receipt.
Sources: FDA CFSAN updates · Federal Register filings · CRN public petitions
Empty corporate boardroom
Twilight, ominous mood
Ask Yourself a Harder Question.
The same agency that tried to pull NMN off the market in 2022 is the same agency whose senior officials routinely retire into pharmaceutical board seats — paying seven figures a year.
This isn't a conspiracy theory. It's public record. The "revolving door" between the FDA and Big Pharma has been documented by Yale Medical School, BMJ, ProPublica, and the agency's own inspector general.
So when you ask "why would the FDA try to take away a $40 supplement?" — the honest answer isn't that they hate consumers. It's that the people who run the agency know exactly who signs their next paycheck.
The Four Molecules That Make This Worth $600 a Month — to Them
Every patent fight in this category targets one of these four. Restore NAD+. Repair the methylation pathway. Clear senescent cells. Activate the longevity gene. The biology is settled. The only question is who gets to sell it to you.
The most direct biological precursor to NAD+. The molecule that triggered the 2022 ban attempt. Forty years of research, billions in investment, one regulatory line item away from being pulled from shelves.
The cofactor every cheap NMN supplement skips — and the reason most NMN-only brands don't work. Without it, supplementing NMN actively depletes the methyl groups your body uses for DNA regulation.
Clears senescent "zombie cells" that accumulate with age and release inflammatory signals. NMN feeds the healthy cells. Quercetin removes the dying ones competing for resources.
Activates SIRT1, the longevity gene that uses NAD+ to repair DNA. Without it, restored NAD+ has nowhere to go to work. The cycle stays broken.
The Same Biology. One-Twelfth the Price.
Identical molecules. Identical doses. Identical mechanisms. The only difference is who's selling it to you, and how much they think they can charge.
Empty IV NAD+ chair
$1,200/session
$1,200 IV Clinic
A two-hour intravenous NAD+ infusion at a private longevity clinic. Effective but expensive — between $800 and $1,500 per session. Most protocols recommend a session every two weeks. Annual cost: $20,000+.
Pharmacy counter
$600/mo branded bottle
$600 Prescription
The version Big Pharma wanted in 2022. Same molecule, in a branded prescription bottle, at pharmaceutical pricing. Estimated monthly cost: $600. Annual cost: $7,200. Insurance coverage: nonexistent for "preventive" longevity use.
Morvalle morning routine
$49.95/mo
$49.95 Morvalle
Same NMN. Same clinical dose. Plus the three cofactors most brands skip. Third-party tested, food-grade, available because the supplement industry fought to keep it legal. Annual cost: $599. The version they don't make a commission on.
Man 60-63, navy sweater
Steady gaze, slight defiance
I worked in pharmaceutical compliance for twenty-three years. I know exactly how that 2022 reclassification happened, who pushed for it, and who walked away with what. I've been on Morvalle for fourteen months. Not because I think the supplement industry is pure — but because I know who the alternative was. I'm not letting them charge me $600 a month for what I can get at clinical dose for $49.
From People Who Won't Be Played Again.
Same Molecule. One-Twelfth the Price.
NMN. TMG. Quercetin. Resveratrol. At the exact clinical doses studied in peer-reviewed human trials, in a third-party-tested formula manufactured to pharmaceutical-grade standards. If a single biotech firm had won in 2022, this protocol would now cost you roughly $600 a month — or $7,200 a year — and you'd need a prescription to get it. Instead, Morvalle delivers all four molecules at the same clinical doses, in one daily capsule, for $49.95. Same biology. Different system.
Protect My ProtocolWhat People Ask Before They Decide
You Can Wait for Them to Try Again.
Or You Can Protect Yours Now.
The 2025 reversal is not permanent. The IND filing is still active. Big Pharma doesn't lose a fight like this and walk away — they wait for the cycle to reset. Take the protocol while it's still on your terms, not theirs.
Protect My Protocol →